Evaluating Evolution of Incidence Rates of Hodgkin Lymphoma Subtypes
the Cancer Therapy Advisor take:
Recent declines in nodular sclerosis (NS) rates represented true incidence changes, whereas long-term rate decreases for mixed cellularity (MC) and increases for non-otherwise specified (NOS) Hodgkin lymphoma (HL) were attributed to evolutions in diagnostic and/or classification practices, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
In this study, the investigators analyzed detailed histology-specific HL incidence rates from 1992 through 2011 using U.S. SEER data (n=21,372) and NOS pathology reports (regional subset from 2007-2011) for insight into diagnostic and classification practices.
Results showed cHL rates that were previously stable decreased after 2007 for whites [annual percent change (APC) and 95% CI: -3.6% (-5.6%, -1.5%)]. Similarly, a decline was observed in NS rates after 2007 by 5.9% annually, varying by gender, age, and race/ethnicity.
Furthermore, between 1992 and 2011, the overall incidence rates for MC and NOS declined (APC -4.0% [-4.7%, -3.3%]) and rose (5.3% [4.5%, 6.2%]), respectively.
There was minimal observation of trends in combined rates, suggesting increasing misclassification of MC, LD, and specific NS subtypes as NOS.
Out of 165 reviewed NOS pathology reports, 88 addressed classification choice. From these 88, 20 (12.1%) justified the classification, 21 (12.7%) had insufficient biopsy material, and 27 (16.4%) reported coders missed specific subtype information.
Recent declines in nodular sclerosis rates represented true incidence changes in Hodgkin lymphoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer